Scarica l'app Stockscreener
25.84
1.81%
0.46
Precedente Chiudi:
$25.38
Aprire:
$25.48
Volume 24 ore:
105.97K
Relative Volume:
1.19
Capitalizzazione di mercato:
$548.94M
Reddito:
$54,000
Utile/perdita netta:
$-210.26M
Rapporto P/E:
-32.71
EPS:
-0.79
Flusso di cassa netto:
$-159.01M
1 W Prestazione:
+13.78%
1M Prestazione:
+8.98%
6M Prestazione:
+138.60%
1 anno Prestazione:
+121.99%
Intervallo 1D:
$25.20
$27.25
Intervallo di 1 settimana:
$21.07
$27.25
Portata 52W:
$7.65
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Nome
Lyell Immunopharma Inc
Settore
Industria
Telefono
650 695-0677
Indirizzo
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
25.84 | 539.17M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-30 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-06-27 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2021-07-12 | Iniziato | BofA Securities | Buy |
| 2021-07-12 | Iniziato | Goldman | Buy |
| 2021-07-12 | Iniziato | JP Morgan | Overweight |
| 2021-07-12 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Lyell Immunopharma Inc Borsa (LYEL) Ultime notizie
Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs - Yahoo Finance
Lyell Immunopharma (NASDAQ:LYEL) COO Stephen Hill Sells 1,236 Shares - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Insider Sells $39,084.69 in Stock - MarketBeat
Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) CEO Sells 7,455 Shares of Stock - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 7.3%Should You Buy? - MarketBeat
Lyell Immunopharma Announces Initiation Of Patient Dosing In First-Of-Its-Kind Phase 3 Car T-Cell Clinical Trial - TradingView
Lyell Immunopharma, Inc. (Lyell) announced that dosing has begun for patients with aggressive large B-cell lymphoma in a groundbreaking Phase 3 clinical trial. - Bitget
Inside the first head-to-head CAR T cancer trial testing Lyell’s ronde-cel - Stock Titan
Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) CEO Sells 438 Shares of Stock - MarketBeat
Is Lyell Immunopharma Inc. stock trending bullishBreakout Watch & Daily Profit Maximizing Tips - mfd.ru
Can Lyell Immunopharma Inc. stock beat market expectations this quarterInsider Selling & Fast Entry High Yield Tips - mfd.ru
Is Lyell Immunopharma Inc. stock gaining market shareJuly 2025 Patterns & Low Risk High Win Rate Stock Picks - mfd.ru
Pullback Watch: Is Lyell Immunopharma Inc stock trending bullishJuly 2025 Setups & Daily Profit Focused Screening - baoquankhu1.vn
How do insiders feel about American Express CompanyIPO Watch & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Growth in Short Interest - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap UpShould You Buy? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Trading 13.4% HigherWhat's Next? - MarketBeat
Earnings Beat: How volatile is Lyell Immunopharma Inc stock2025 Technical Patterns & Smart Allocation Stock Tips - baoquankhu1.vn
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update - Defense World
Entry Recap: Will Lyell Immunopharma Inc benefit from rate cutsExit Point & AI Forecast for Swing Trade Picks - baoquankhu1.vn
EPS Watch: What is the long term forecast for Lyell Immunopharma Inc stockPrice Action & Advanced Technical Signal Analysis - baoquankhu1.vn
How rising interest rates impact Lyell Immunopharma Inc. stock2025 Major Catalysts & AI Optimized Trading Strategy Guides - Улправда
Will Lyell Immunopharma Inc. stock benefit from automation2025 Price Targets & Fast Entry Momentum Trade Alerts - ulpravda.ru
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4.6%Here's Why - MarketBeat
Should I hold or sell Lyell Immunopharma Inc. stock in 2025Market Profile Overview & Low Cost Wealth Investment - bollywoodhelpline.com
Lyell Immunopharma (NASDAQ:LYEL) Shares Up 4.2%Still a Buy? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Trading Down 6.7% – Should You Sell? - Defense World
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 6.7%Here's Why - MarketBeat
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL) - Defense World
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Yahoo Finance
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data (NASDAQ:LYEL) - Seeking Alpha
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
Lyell Immunopharma (NASDAQ:LYEL) Shares Up 5.5%Here's Why - MarketBeat
Lyell ImmunoPharma pops on recent ASH data, immunotherapy expansion - MSN
Lyell Immunopharma (NASDAQ:LYEL) Reaches New 1-Year HighTime to Buy? - MarketBeat
Lyell Immunopharma pops on recent ASH data, immunotherapy expansion - Seeking Alpha
Why Lyell Immunopharma Inc. stock could be next big winnerPortfolio Growth Summary & High Win Rate Trade Tips - Улправда
Will Lyell Immunopharma Inc. stock rally after Fed decisionsGold Moves & High Accuracy Swing Trade Signals - Улправда
Would You Still Hold Lyell Immunopharma Stock If It Fell 30%? - Trefis
Dip Buying: Is Lyell Immunopharma Inc. stock a smart buy before Fed meeting2025 Market Trends & Free Expert Verified Stock Movement Alerts - Улправда
What technical charts say about Lyell Immunopharma Inc. stock2025 Trading Recap & Risk Controlled Stock Pick Alerts - DonanımHaber
What analysts say about Lyell Immunopharma Inc stockGap Up/Gap Down Analysis & Free Rapid Wealth Building - earlytimes.in
CEO Change: Why Lyell Immunopharma Inc. stock could be next big winnerBond Market & Consistent Profit Trading Strategies - Улправда
Can Lyell Immunopharma Inc. stock reach $100 price target2025 Earnings Impact & Daily Profit Focused Screening - DonanımHaber
Is Lyell Immunopharma Inc. stock a safe buy before earningsPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - Улправда
Why Lyell Immunopharma Inc. stock could outperform in 20252025 Major Catalysts & Intraday High Probability Setup Alerts - DonanımHaber
Is Lyell Immunopharma Inc. stock a smart buy before Fed meetingJuly 2025 Chart Watch & Technical Pattern Recognition Alerts - Улправда
Lyell Immunopharma (LYEL) details 1.9M-share ICT resale and license terms - Stock Titan
Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain - Yahoo Finance
Lyell Immunopharma climbs after reporting strong CAR T-cell therapy results - MSN
Lyell Immunopharma Inc Azioni (LYEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lyell Immunopharma Inc Azioni (LYEL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hill Stephen J. | Chief Operating Officer |
Feb 11 '26 |
Sale |
23.39 |
1,236 |
28,910 |
17,795 |
| Lee Gary K. | Chief Scientific Officer |
Feb 11 '26 |
Sale |
23.39 |
1,671 |
39,085 |
16,938 |
| Hill Stephen J. | Chief Operating Officer |
Feb 10 '26 |
Sale |
23.12 |
109 |
2,520 |
19,031 |
| Lee Gary K. | Chief Scientific Officer |
Feb 10 '26 |
Sale |
23.12 |
147 |
3,399 |
18,609 |
| Seely Lynn | President and CEO |
Feb 10 '26 |
Sale |
23.12 |
438 |
10,127 |
81,721 |
| Bulis Veronica Sanchez | VP, Corporate Controller |
Feb 10 '26 |
Sale |
23.12 |
254 |
5,872 |
15,637 |
| Bulis Veronica Sanchez | VP, Corporate Controller |
Dec 24 '25 |
Sale |
38.67 |
1,136 |
43,929 |
8,077 |
| Bulis Veronica Sanchez | VP, Corporate Controller |
Dec 30 '25 |
Sale |
32.32 |
936 |
30,252 |
7,141 |
| Seely Lynn | President and CEO |
Nov 10 '25 |
Sale |
16.11 |
412 |
6,637 |
67,159 |
| Bulis Veronica Sanchez | VP, Corporate Controller |
Nov 10 '25 |
Sale |
16.10 |
239 |
3,848 |
9,213 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):